AIM ImmunoTech advances Ampligen for avian influenza vaccine
Inc. (NYSE American: AIM) has announced its intention to develop Ampligen as a vaccine adjuvant for avian influenza. This ...
Zacks Small Cap Research on MSN51 分钟
DYAI: Looking Toward Product Revenues
DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) enters 2025 on the cusp of generating product revenues from its relationship with Proliant. Initially, commercialization ...